ADHD Stimulants — Inherited Patient

At minimum, check at the first appointment with a new-to-you patient and at every controlled substance renewal thereafter. Quarterly checks at prescription renewal visits are a reasonable standard for stable patients.

New York State requires PDMP review prior to prescribing controlled substances. This is a legal obligation, not a preference.

Red flags that warrant pause before prescribing:

Multiple prescribers — stimulants from more than one provider in the past 12 months without clear documented coordination.

Multiple pharmacies — controlled substances filled at 3+ pharmacies without a clear geographic or insurance reason.

Concurrent opiates — stimulants plus opioids without documented pain management rationale.

Dose mismatch — quantity dispensed doesn't match what any single prescriber would authorize (suggests supplemental sourcing).

Reassuring pattern — same prescriber, same pharmacy, consistent quantity, no gaps suggesting diversion, no overlapping controlled substances.

Do not prescribe at this visit. Have a direct, non-accusatory conversation with the patient: "I'm seeing some things in the prescription history I want to understand before we go further."

Document exactly what you found and what the patient told you. This is protective for you and the institution regardless of what you decide next.

If the concern is significant, this is an appropriate trigger for an e-consult to psychiatry with the specific question of safe prescribing plan rather than routine review.

Yes — when you become the prescriber of record, the documentation obligation transfers to you. The prior provider's omission is their liability, not yours, but it does mean your first check is essential before issuing your first prescription.

Think of it as a brief triage at the first handoff appointment. It takes under two minutes and is your best protection.

Not automatically — but it shifts the burden of documentation significantly. A patient in sustained, well-documented remission who has been stable on stimulants for years is a different clinical picture than a patient with active use.

The key question: is the current prescription part of a coordinated plan, or did it evolve informally without the SUD history being factored in?

If there's no documented awareness of the SUD history in the prior prescribing record, this is a case for psychiatry e-consult — not to decide whether to continue, but to have a documented expert review in the chart.

At minimum: a note that the provider is aware of the SUD history, has considered it in the prescribing decision, and has a monitoring plan. This can be brief.

Example language: "Patient has history of [SUD], currently in remission x [timeframe]. Stimulant therapy reviewed in this context. Continued with close monitoring including PDMP review at each renewal and urine drug screen [frequency]."

SmartPhrase .CSADHD-SUD-AWARE covers this documentation.

Cannabis use alone does not automatically disqualify a patient from stimulant continuation, but it should be documented and acknowledged. The concern is whether cannabis use represents a broader pattern of substance use that increases misuse risk.

Heavy or problematic cannabis use warrants the same documentation escalation as any other SUD history. Occasional use in a stable, well-functioning patient is a clinical judgment call — document your reasoning either way.

You're assessing current functional status, not comparing to a baseline you never witnessed. Ask directly: "How are things going at work / school / home? Are you managing the things you were struggling with before medication?"

If the patient can describe specific, credible improvements in function — and there's no evidence of dose escalation, misuse, or new concerns — that's a reasonable basis for continuation.

You're not re-validating the original diagnosis. You're verifying that an ongoing prescription is doing what it's supposed to do.

This is a clinical judgment call that doesn't have a bright-line answer. A few considerations:

Is there corroboration? Prior notes from a previous provider, a therapist, a partner or employer? Even a prior rating scale in the chart?

Are there behavioral inconsistencies? Does the patient's presentation, history, or PDMP pattern suggest misuse or diversion rather than treatment?

If your clinical instinct is firing and you can't articulate why you're comfortable, that's the moment to pause, document, and consider an e-consult. That consult is not punitive — it's you doing exactly what the framework asks.

Formal rating scales (Adult ADHD Self-Report Scale, Conners Adult ADHD Rating Scale) are better suited to initial evaluation and are not expected at every follow-up for established patients.

Brief structured questions — functional domains, side effects, adherence — are sufficient and documentable for ongoing management. The goal is a consistent, reproducible assessment, not a diagnostic workup at every visit.

A single request more than 5 days early is worth a conversation. A pattern of requests more than 5 days early across multiple fill cycles is a red flag warranting documentation and possible escalation.

Context matters: a patient who ran out early once because of a vacation schedule is different from a patient who consistently fills 10 days early over 12 months.

Pattern: 2+ early fills in 12 months — document, address directly with patient, consider urine drug screen.

New York State Schedule II controlled substances (most stimulants) cannot be post-dated or filled early beyond the state dispensing window, regardless of reason. Patients traveling internationally should plan ahead with their prescribing provider well in advance — this is not something that can be resolved at the last minute.

For domestic travel, most pharmacies can fill within a few days of the allowed window. Counsel patients to plan accordingly.

Lost or stolen Schedule II controlled substances are not replaced as a matter of policy. This is both a regulatory constraint and a risk management position.

Communicate this clearly and without apology: "I understand this is frustrating. Unfortunately, Schedule II medications can't be replaced in these circumstances — this is a regulatory requirement, not a decision I'm making about you personally."

Document the report, check the PDMP, and note the conversation. A single loss event is not necessarily disqualifying for continued prescribing, but it should be in the chart.

You are not responsible for the prior diagnostic process, but you are responsible for decisions made from this point forward. Continuing a prescription is a clinical decision — meaning it's yours, and it should be defensible.

The question isn't "was this diagnosis legitimate?" It's "do I have enough information to comfortably continue this medication?" If the answer is no, the e-consult pathway exists precisely for this situation.

Neuropsychological testing is not required for an ADHD diagnosis and is not the standard of care in most clinical settings. A reasonable workup includes:

A validated rating scale (e.g., Adult ADHD Self-Report Scale) completed by the patient. A structured clinical interview addressing symptom onset, duration, and functional impairment across settings. Consideration of differential diagnoses — anxiety, mood disorders, sleep disorders, and thyroid disease can all mimic ADHD.

If none of this is in the chart, that's thin — but it's a very common chart. The e-consult purpose here is to get a psychiatrist's eyes on the case so you have expert documentation in the record. It changes the risk profile for both of you.

Clinically, a 5-year stable course with demonstrated functional benefit is meaningful evidence in its own right. The medication is clearly doing something for this person.

That said, "doing something" doesn't always mean treating ADHD — stimulants improve focus and executive function across many conditions and in some people without a formal diagnosis. The diagnostic question remains open.

For practical purposes: a long-stable patient with no red flags and a thin chart is a lower priority for formal re-evaluation than a recent diagnosis, a request to escalate dose, or emerging behavioral concerns. Use clinical judgment on triage order.

Amphetamine salts (Adderall) — FDA max 60 mg/day for adults. Doses above 40 mg/day in primary care warrant documentation of rationale.

Methylphenidate (Ritalin, Concerta) — FDA max 60 mg/day. Extended-release formulations vary by product; check prescribing information.

Lisdexamfetamine (Vyvanse) — FDA max 70 mg/day. This is a hard ceiling due to the prodrug formulation.

Doses above FDA maximum are outside this framework and require specialist co-management.

Continuing a maximum-dose prescription is within primary care scope if it's clinically justified and documented. The burden of documentation is higher at the ceiling than at moderate doses.

At first visit: review the chart for the rationale behind escalation. If it's documented and coherent — continue with your own documented review.

If there's no documented rationale for the ceiling dose — or if the escalation happened recently and rapidly — this is an e-consult trigger. The question for psychiatry: "Patient is at maximum dose of [medication] without clear documented rationale. Please review current plan and advise whether to maintain, taper, or restructure."

Behavioral red flags in this context are signs that the medication may be causing harm, being misused, or masking an underlying condition that's worsening:

Mood instability — new or worsening irritability, emotional dysregulation, or rage that the patient or family attributes to medication timing.

Sleep severe enough to impair function — beyond expected stimulant effect, especially if the patient is escalating to cope.

Cardiovascular symptoms — palpitations, chest pain, or significant blood pressure elevation at current dose.

Increasing psychological dependence — patient describes inability to function at all without the medication in ways that feel qualitatively different from therapeutic benefit.

Yes — and this is one of Dr. Batson's core concerns about the diagnostic rigor of many adult ADHD diagnoses. Anxiety disorders, bipolar disorder (particularly type II), and PTSD all significantly overlap with ADHD symptom profiles.

Stimulants can worsen anxiety, destabilize mood in bipolar disorder, and in some cases worsen trauma-related hyperarousal. If a patient is deteriorating on stimulants, these are worth considering.

This doesn't mean stopping the medication unilaterally — it means this patient needs psychiatric input, and the e-consult should frame that question explicitly.

Combination stimulant therapy (e.g., long-acting amphetamine plus short-acting methylphenidate) exists in clinical practice, particularly in severe ADHD managed by specialists. It is outside the scope of primary care initiation and requires specialist documentation.

If a patient arrives already on a multi-agent regimen, this is a situation where the e-consult precedes any continuation decision — not to refuse, but to have expert sign-off in the chart before you own this prescription.

Adding a short-acting "booster" to a long-acting regimen is common in specialist practice and not inherently inappropriate. But initiating this in primary care without specialist guidance or documentation is high-exposure territory.

The conversation with the patient: "That's a reasonable clinical question. I want to make sure we approach it the right way, which means getting a psychiatry review before we add anything new to your regimen. I'm not saying no — I'm saying let's do this properly."

This is precisely the e-consult scenario: patient-requested escalation requiring specialist input before action.

Restarting a previously prescribed regimen is lower risk than initiating something new, especially if it's documented in prior records. The PDMP will show whether this was previously dispensed.

If the prior prescribing record shows the combination was used, was safe, and was discontinued for a non-clinical reason (e.g., provider left the practice), continuation with documentation is defensible.

If you're not comfortable, the e-consult is always available. That's not a failure — that's the framework doing its job.

High-priority nephrotoxins to review in any CKD patient:

NSAIDs (including OTC ibuprofen/naproxen) — counsel to discontinue.

Metformin — generally safe to eGFR 30, reduce monitoring frequency below 45, hold below 30.

SGLT2 inhibitors — reassess below eGFR 45 (varies by agent and indication).

ACE inhibitors / ARBs — do not discontinue for mild creatinine bump (up to 30% rise is acceptable and expected); do reassess if rise exceeds that threshold.

Gabapentin/pregabalin — dose reduction required below eGFR 60.

Renally-cleared antibiotics — flag for any acute prescribing: nitrofurantoin contraindicated below eGFR 45.

In CKD G3a and above (eGFR < 60), the recommendation is to discontinue chronic NSAID use. Have a direct conversation: frame it as protecting kidney function, not removing pain management.

Offer alternatives — acetaminophen, topical diclofenac for localized pain, or a warm handoff to pain management if the underlying condition warrants it. Document the conversation and the plan.

For common medications with well-established renal dosing (metformin, gabapentin, many antibiotics), adjust now using the eGFR-based thresholds above. Do not wait for nephrology to make changes that are your responsibility as the PCP.

The e-consult is for guidance on management strategy — not for permission to stop nephrotoxins.

Creatinine-based eGFR is affected by muscle mass, diet, and race — it systematically overestimates GFR in patients with low muscle mass (elderly, frail, malnourished) and can underestimate in bodybuilders.

Cystatin C is filtered at a constant rate regardless of these variables. The CKD-EPI 2021 equation using both markers is now the preferred standard. When cystatin C eGFR is meaningfully lower than creatinine eGFR, believe cystatin C — it's the more accurate number.

Often yes. This is the most common anxiety point with cystatin C adoption. The lower number is not an error — it's a more accurate reflection of true GFR, particularly in older or leaner patients.

Stage and manage based on the cystatin C result. If this moves the patient into a higher-risk category, that's exactly the information you needed.

Albuminuria is an independent risk factor for CKD progression and cardiovascular disease, separate from eGFR. A patient can have eGFR 65 with uACR > 300 and be at higher risk than a patient with eGFR 52 and uACR < 30.

Staging requires both dimensions — the G stage (eGFR) and the A stage (albuminuria). You cannot complete a CKD staging without it.

Ideally yes — a fresh midstream catch within 2 hours of collection gives the most reliable microscopy, particularly for RBC morphology. If the patient is in office, collect it that day.

If ordering remotely, instruct accordingly and note in the order.

Using CKD-EPI 2021 cystatin C-based eGFR:

G1: ≥ 90 — Normal or high. CKD diagnosis requires other markers (albuminuria, structural abnormality). Monitor.

G2: 60–89 — Mildly decreased. Monitor annually if stable.

G3a: 45–59 — Mildly to moderately decreased. Begin medication review, BP optimization, RAAS therapy if proteinuric.

G3b: 30–44 — Moderately to severely decreased. Nephrology e-consult appropriate. Begin anemia workup, mineral/bone disease labs.

G4: 15–29 — Severely decreased. Nephrology referral (not just e-consult). RRT planning discussion begins.

G5: < 15 — Kidney failure. Active nephrology co-management required.

Three things: (1) Start or optimize an ACE inhibitor or ARB if they have albuminuria or diabetes — this is the single highest-impact intervention in early CKD. (2) Get BP below 120/80 if tolerated. (3) Counsel on nephrotoxin avoidance and dietary sodium restriction.

An SGLT2 inhibitor is indicated if they have diabetes or heart failure — this is now a standard of care intervention, not a specialist decision.

Yes — this is a diagnosis, and it should be documented and communicated as such. Many patients with CKD G3 have been managed for years without anyone saying the words. Naming it clearly allows the patient to understand the stakes, engage in self-management, and make informed decisions.

Use plain language: "Your kidneys are working at about X% of normal. This is a condition called chronic kidney disease. It's manageable and we caught it at a stage where we can do a lot to protect them."

Current KDIGO 2021 guidelines recommend a target of < 120 mmHg systolic if tolerated, based on SPRINT trial data. This is a meaningful shift from the older 130/80 standard.

In practice, tolerability is the limiting factor — orthostatic symptoms, syncope risk in elderly patients, and baseline hypotension all require individualization. Document your target and your rationale.

ACE inhibitor or ARB is first-line in CKD with albuminuria (uACR > 30) or diabetes, regardless of BP. Do not use both together — dual RAAS blockade increases harm without added benefit.

For additional BP control: dihydropyridine calcium channel blockers (amlodipine) and thiazide-like diuretics (chlorthalidone preferred over HCTZ in CKD) are appropriate add-ons. Loop diuretics for volume management in G4–G5.

Not automatically. A rise in creatinine of up to 30% after initiating an ACE inhibitor or ARB is expected, acceptable, and does not indicate harm — it reflects the intended hemodynamic effect on the glomerulus.

Recheck in 2 weeks. If the rise is greater than 30% or potassium rises above 5.5, then hold and reassess. If you stop every ACE inhibitor that causes any creatinine bump, you will deprive CKD patients of their most protective therapy.

Pull prior creatinine values from the chart — at minimum 12 months back, ideally 24. Calculate the trajectory. A decline of more than 5 mL/min/1.73m² per year is considered rapid and warrants e-consult regardless of current stage.

A single low value without prior data is not the same as demonstrated progression — establish the trend first.

Yes — always rule out AKI superimposed on CKD before concluding progression. Recent illness, volume depletion, new nephrotoxin exposure, or urinary obstruction can all cause acute drops.

If there's any question, recheck in 4–6 weeks after addressing potential acute factors before framing as progression.

Several things happen simultaneously at G4 that go beyond standard PCP management:

(1) Nephrology referral (not just e-consult) is indicated. (2) Mineral and bone disease workup: PTH, phosphorus, 25-OH vitamin D, calcium. (3) Anemia of CKD evaluation. (4) RRT planning conversation — not to alarm, but to inform. Patients who arrive at dialysis having never discussed it are poorly prepared.

ESA initiation in CKD is a nephrology decision. Your role at G4 is to identify anemia, complete the workup (iron studies, B12, folate, retic count), correct iron deficiency if present, and document.

The e-consult to nephrology should include this workup so they can advise on ESA candidacy with full information in hand.

Not necessarily — nephrotic range proteinuria is traditionally defined as > 3.5 g/day on 24-hour urine, or roughly uACR > 2000–3500 mg/g. A uACR of 300–2000 is severely increased but not nephrotic.

However, any uACR > 300 warrants e-consult regardless of eGFR, as it indicates significant glomerular pathology and accelerated progression risk.

A single elevated uACR should be confirmed on a second sample (ideally first morning void) before staging — transient elevations occur with fever, exercise, and UTI.

However, if the value is markedly elevated (> 300) and there's no obvious transient cause, begin the workup in parallel with confirmation rather than waiting.

This is the e-consult indication — unexplained CKD requires nephrology input to consider glomerulonephritis, genetic nephropathy, or other primary renal disease.

Before the consult, complete: urinalysis with microscopy (looking for casts), uACR, renal ultrasound, serum protein electrophoresis in patients > 40 (to screen for myeloma), ANA and complement if clinical picture suggests autoimmune.

Document what you've ruled out — the nephrologist can then focus on what remains.

Dysmorphic RBCs — particularly acanthocytes — on urine microscopy indicate glomerular origin of bleeding, as opposed to urothelial sources (stone, tumor, infection). This is a nephrology finding, not a urology finding.

If the microscopy report specifically mentions dysmorphic RBCs or acanthocytes, the e-consult goes to nephrology, not to urology for cystoscopy.

Standard urinalysis does not assess morphology — that requires microscopy with a trained eye. If you have > 5 RBCs/hpf on two separate specimens without an obvious benign cause, request formal microscopy.

In many practices this requires a specific order or a call to the lab.

The stakes are higher and the patterns are more specific. For opiates you are looking for: overlapping fills from any prescriber (suggests double-doctoring), concurrent benzodiazepine prescriptions (this is your most important safety flag — the combination dramatically increases overdose mortality), fill frequency relative to days supply (filling a 30-day supply every 20 days is a pattern), and cash-pay fills which bypass insurance tracking and may not appear on PDMP in all states.

New York requires PDMP review prior to every opiate prescription — not just at intake.

Not automatically — but it requires an explanation you can document. A patient seeing both a PCP and a pain management specialist may have legitimate dual prescribing if it is coordinated. An ER prescription for an acute injury is different from a pattern of monthly fills from two separate primary care offices.

Ask the patient directly, document what they tell you, and contact the other prescriber if the answer is unclear.

Do not prescribe the opiate at this visit without a safety plan. The opiate-benzodiazepine combination is the leading driver of prescription overdose mortality. This is not a reason to cut the patient off — it is a reason to have a direct conversation, understand who is managing the benzo, and develop a coordinated plan.

See the escalation FAQ for next steps.

Yes. When you become the prescriber of record, a new agreement should be completed. This is both a documentation standard and a clinical moment — reviewing the agreement with the patient at the first visit establishes expectations, gives you an opportunity to assess their understanding, and signals that this is a managed relationship, not an automatic continuation.

At minimum: single prescriber and single pharmacy requirements, agreement to UDS monitoring, no early refills policy, no replacement for lost or stolen medications, expectations around dose changes (patient does not self-adjust), and acknowledgment that the goal of therapy is functional improvement, not pain elimination.

SmartPhrase .CSAGREE populates the standard institutional template.

A patient who refuses to sign a CS agreement is communicating something worth understanding before you respond. Ask why — occasionally there is a literacy or language barrier, or a prior negative experience with how the agreement was presented.

If refusal is categorical and the patient cannot articulate a reason, document the refusal and the conversation. You are not obligated to prescribe without a signed agreement, and the institutional framework supports that position.

The point-of-care immunoassay (the cup test) is a screen — it is fast and useful but has meaningful false positive and false negative rates. A positive screen for an unexpected substance, or a negative screen for the prescribed opiate, should be confirmed with GC-MS or LC-MS/MS before you act on it clinically or document it as a confirmed finding.

Do not discharge a patient based on a screen alone.

Several possibilities: the patient did not take the medication as prescribed (most concerning — suggests diversion or stockpiling), the patient took it but timing of the dose relative to collection caused a false negative (less common with chronic dosing), or there is a metabolic variant affecting detection.

Confirm with send-out testing. Have a non-accusatory conversation: "I want to make sure we understand this result together before drawing any conclusions." Document the conversation and the plan for follow-up testing.

Risk-stratified. A stable patient with a clean PDMP, signed agreement, and no behavioral concerns: every 6–12 months is a defensible standard. A patient with any yellow flags: every 3 months. A patient with active concerns or recent escalation: at every visit until stable.

Document your reasoning for the interval chosen.

Multiply the daily dose by the conversion factor for that opioid:

Morphine — 1:1 (30 mg morphine = 30 MME)

Oxycodone — × 1.5 (30 mg oxycodone = 45 MME)

Hydrocodone — × 1 (30 mg hydrocodone = 30 MME)

Hydromorphone — × 5 (8 mg hydromorphone = 40 MME)

Fentanyl patch — mcg/hr × 2.4 (25 mcg/hr patch = 60 MME/day)

Tramadol — × 0.1 (200 mg tramadol = 20 MME)

For patients on multiple opiates, sum the MME of all agents.

CDC guidance identifies key inflection points:

50 MME/day — increased overdose risk begins; reassess benefit/risk, ensure naloxone is prescribed and patient and household are trained.

90 MME/day — avoid prescribing above this threshold without documented specialist involvement and clear clinical rationale. This is not a hard ceiling but a high-scrutiny zone. Above 90 MME without pain management co-management is an escalation indicator in this framework.

Stability is meaningful clinical information. Abrupt taper of a long-stable high-dose patient causes harm — undertreated pain, withdrawal, loss of function, and in some cases drives patients to illicit opioids. Do not taper at the first visit.

Complete the intake assessment, establish the relationship, prescribe with full documentation of your awareness of the dose and your clinical rationale for continuation, and use the e-consult to get pain management eyes on the chart. The question for the consult is: "Patient stable on X MME/day for Y years. Please review and advise on whether current plan is appropriate or whether structured taper is indicated."

Yes — for any patient on ≥ 50 MME/day, any patient on opiates plus any CNS depressant, any patient with a history of SUD or overdose, and any patient whose household includes children or others at risk of accidental exposure.

Document that you prescribed it, that you counseled on administration, and that the household has access to it. This is now a standard of care expectation, not an optional add-on.

Yes — do not abruptly discontinue or reduce at the first visit while awaiting specialist input. Continuity of an established regimen while arranging appropriate oversight is clinically and ethically defensible.

Document your dose calculation, your awareness of the threshold, your safety measures (naloxone prescribed, UDS obtained, PDMP reviewed), and that e-consult to pain management is pending.

Be specific: "Patient inherited on [X] MME/day of [agent] for [indication]. No prior pain management documentation in chart. PDMP clean, UDS confirms prescribed medication, patient reports functional stability. Please review current regimen and advise: (1) whether dose is appropriate for indication, (2) whether structured taper is recommended, and (3) whether ongoing co-management is indicated."

Acknowledge the anxiety without making promises you can't keep: "I understand this medication has been important to your quality of life and I'm not here to take anything away from you today. I do need to complete my own assessment as your new provider, and I want to make sure we're doing this in a way that protects you."

Do not let the threat of patient departure drive clinical decisions. Document the conversation.

It is the most dangerous combination in outpatient prescribing. Concurrent opioid and benzodiazepine use increases overdose mortality risk by a factor of 3–4 compared to opioids alone. Both drug classes cause respiratory depression through different mechanisms — the combination is synergistic, not additive.

The FDA issued a black box warning on this combination in 2016. You cannot inherit this combination and continue it unchanged without a documented safety plan and specialist input.

This is precisely the e-consult scenario. The question is not whether either medication is individually justified — it is whether the combination is the safest available approach given the full clinical picture. Psychiatry or pain management input, depending on which medication is driving the combination, is required before you own both prescriptions.

At this visit: prescribe whichever is the more immediately necessary (typically the opiate if chronic pain is the primary indication), document the combination as a known risk, prescribe naloxone, and initiate the e-consult urgently.

Benzo taper in the context of chronic use requires its own careful management and is not something to initiate unilaterally at a first visit. A patient on chronic benzodiazepines is physically dependent — abrupt reduction risks withdrawal seizure.

The taper plan should be coordinated, ideally with psychiatry input, and should be separate from the opiate management conversation so the patient is not facing two simultaneous tapers.

Confirm with send-out testing before taking action. If confirmed: do not prescribe at this visit. Have a direct, non-punitive conversation focused on safety: "I'm concerned about your safety if we combine these substances." Document the conversation.

This is an OUD evaluation trigger — consider whether what you're seeing is active substance use disorder that warrants MOUD rather than simply discontinuing the opiate. A patient with OUD who is cut off from prescribed opioids without treatment is at significantly elevated overdose risk from illicit opioid use.

This is a high-acuity finding. Illicit fentanyl exposure indicates the patient is using street opioids — either supplementing their prescription or substituting for it. This is an OUD evaluation and MOUD conversation, not a straightforward prescription continuation decision.

Do not prescribe additional controlled substances at this visit. Engage with empathy: the patient is at serious overdose risk and needs treatment, not termination from the practice.

It is a red flag that requires explanation — it is not a confirmed finding. Ask directly and document the answer. Geographic reasons (pharmacy closures, travel, insurance network restrictions) are plausible. A pattern of cash-pay fills at multiple locations without a coherent explanation is more concerning.

Confirm with send-out UDS to establish whether the patient is actually taking the medication. If the pattern is unexplained and confirmed, this is a case for e-consult before continuing.

Document exactly what you found (dates, prescribers, pharmacies, quantities), what you asked the patient, what they told you, and what your clinical assessment is. This documentation protects you regardless of what you decide.

If you choose to continue prescribing despite a flag, document your reasoning. If you choose not to prescribe, document your safety plan for the patient.

1 request — warrants a conversation and documentation.

2+ in 12 months — warrants a formal written warning within the CS agreement framework, a UDS, and a PDMP review.

3+ in 12 months — a pattern that requires e-consult before continuation.

Document each instance at the time it occurs — patterns are only visible in retrospect if the individual events are in the chart.

Establish a clear protocol and communicate it once, in writing: controlled substance questions are addressed at scheduled visits only, not by phone or portal message. Exceptions are not made between visits. Document that this was communicated.

Frequent between-visit contact around controlled substances is itself a behavioral flag — note it in the chart as part of the monitoring picture.

Schedule II opiates are not replaced for loss or theft as a matter of institutional policy. Communicate this clearly and without apology. You may offer to file a police report with the patient if they wish to document the theft — this creates a record and is occasionally relevant.

Document the report in the chart. A single loss event is not disqualifying for future prescribing, but it should be noted and factored into the monitoring picture going forward.

They coexist more often than they are mutually exclusive — a patient can have both legitimate chronic pain and opioid use disorder simultaneously. Signs that OUD may be present alongside or instead of pure pain management need:

Continued use despite clear harm, inability to adhere to the agreed prescribing structure despite genuine effort, loss of control over use, withdrawal symptoms driving use more than pain relief, and social or functional deterioration attributable to opioid use.

MOUD — medication for opioid use disorder — is the evidence-based treatment and significantly outperforms taper or discontinuation for patient outcomes including overdose survival. Buprenorphine (Suboxone) can be initiated in primary care and is within your scope. Methadone for OUD requires an OTP clinic.

The e-consult framing shifts: instead of "please review pain management plan," it becomes "patient with chronic pain and possible OUD — please advise on MOUD candidacy and transition plan." Do not frame OUD as a moral failure to the patient or in documentation.

Yes — do not abruptly discontinue while the evaluation is pending. A patient who is cut off from prescribed opioids without a treatment plan is at acute overdose risk from illicit opioid use.

Continuity with close monitoring and an active referral in process is safer than discontinuation without a plan.

For benzodiazepine patients the critical flags are: concurrent opiate prescriptions (see escalation section — this is the most dangerous combination in outpatient prescribing), Z-drug co-prescriptions (zolpidem plus a benzodiazepine doubles CNS depression risk), fills from multiple prescribers without documented coordination, and quantities that exceed what a single prescriber's regimen would generate.

Also look for recent ER visits — patients in benzo withdrawal or toxicity frequently present to emergency departments and this may appear in shared records but not the PDMP itself.

No — benzodiazepines should have a single prescriber. If a psychiatrist is managing the underlying indication, the psychiatrist should own the prescription. If the patient is transitioning care and the psychiatrist is no longer involved, document the gap and initiate a warm handoff or e-consult before you assume the prescription.

Two providers co-prescribing the same controlled substance class without explicit coordination is a liability for both and a safety risk for the patient.

New York State requires PDMP review prior to every Schedule IV controlled substance prescription. Benzodiazepines are Schedule IV. This is a legal requirement at every prescribing encounter, not just at intake.

This is extremely common and does not by itself require you to stop prescribing. Your task is to establish an indication going forward — even if the original rationale is lost to history.

Conduct a brief structured assessment at this visit: What symptoms does the medication treat? What happens when doses are missed? Is there an underlying anxiety disorder, panic disorder, or other condition that a proper diagnosis would capture? Document your clinical impression as the current indication. If no legitimate indication can be established, this is an e-consult trigger — not a reason to stop today.

No — benzodiazepines are not indicated for chronic insomnia management and are not approved for this use long-term. If insomnia is the only documented indication, the patient likely has physical dependence without an ongoing therapeutic justification.

This does not mean immediate taper — it means the e-consult framing is "patient on chronic benzodiazepine for insomnia indication, no psychiatric diagnosis on file, please advise on taper planning and alternative management." CBT-I (cognitive behavioral therapy for insomnia) is the evidence-based first-line treatment and can be initiated in parallel.

Anxiety disorders are among the most underdiagnosed conditions in primary care. A patient who has been on a benzodiazepine for years for "nerves" or "stress" may have an untreated anxiety disorder that was managed symptomatically rather than definitively.

Administering a GAD-7 at this visit takes four minutes and gives you a documented baseline. If the score is significant, you now have a diagnosis, a severity measure, and a rationale for the medication — as well as a basis for discussing whether an SSRI or SNRI plus therapy would be a more appropriate long-term approach.

Physical dependence can develop within 4–6 weeks of daily use. Any patient using a benzodiazepine daily for more than 4 weeks should be considered potentially physically dependent and managed accordingly — meaning no abrupt discontinuation under any circumstances.

Duration beyond 6 months with daily use represents established dependence in most patients regardless of dose.

Yes, but the timeline is long and the process requires patient partnership. A decade of daily benzodiazepine use is not resolved over weeks or months — a successful taper may take one to two years using a structured protocol (typically a diazepam conversion with gradual reduction).

The first visit is not the moment to introduce this. The first visit is the moment to establish trust, complete the assessment, and plant a seed: "My goal over time is to make sure you're on the lowest dose that keeps you functional and safe. We're not changing anything today, but I want that to be our shared direction." Document this framing.

Diazepam conversion is a taper strategy, not a first-visit intervention. Its advantage is a long half-life that allows for smoother reduction with less interdose withdrawal.

This conversion is appropriate to plan in coordination with psychiatry e-consult, not to initiate unilaterally at a handoff visit. Document it as a future goal if relevant.

You are looking for evidence that the medication is providing net benefit versus harm at the current dose.

Preserved function — employed or engaged in meaningful daily activity, able to drive safely, maintaining relationships, no falls in the past 12 months, no memory complaints beyond baseline.

Functional impairment — daytime sedation affecting work or safety, falls or near-falls, cognitive complaints, social withdrawal, inability to function without the medication at all (beyond expected physical dependence).

Benzodiazepines impair driving — this is well-established and dose-dependent. You have a clinical obligation to counsel the patient about impaired driving risk and document that you did so.

In New York, physicians do not have a mandatory reporting obligation for medication-impaired drivers equivalent to seizure disorders, but the documentation of your counseling is your protection. If the patient is in a safety-sensitive occupation (commercial driver, healthcare worker, heavy machinery operator), this requires explicit conversation and documentation.

Take it seriously — they are likely correct that they cannot function without it in the short term, because physical dependence is real. Validate this: "I believe you, and I'm not suggesting you stop taking it. What I want to understand is whether the medication is helping you live the life you want, or whether it has become something you need just to feel normal."

This distinction — therapeutic benefit versus dependence maintenance — is the clinical and ethical core of the long-term benzo management question.

Do not prescribe both at this visit without a safety plan in place. This is the single highest-risk combination in outpatient prescribing — the FDA black box warning is unambiguous.

At this visit: assess which medication is primary (which indication is more severe, which has been in place longer), prescribe whichever is more immediately necessary with a one-time bridge supply if needed, prescribe naloxone and counsel the patient and household on administration, and initiate urgent e-consults to the appropriate specialists — psychiatry for the benzo indication, pain management for the opiate, or a combined consult if available.

No adverse event to date is not the same as safe. The combination increases overdose mortality risk regardless of individual tolerance. The absence of prior harm reflects probability, not immunity — and the probability of harm increases with duration of combined exposure.

"They've been fine so far" is not a documentable clinical rationale for continuing a black-box combination without specialist input.

The taper of a patient on both opiates and benzodiazepines requires coordination between providers. As the PCP you own the care coordination — you do not necessarily own the execution of both tapers.

The general principle is to taper one at a time, slowly, with the higher-risk agent (usually the benzodiazepine in terms of seizure risk) addressed with specialist guidance. The e-consult is not a hand-off — you remain the primary care provider. It is a request for a specific plan.

Common benzodiazepine to diazepam equivalents (approximate):

Diazepam 5 mg = reference standard

Alprazolam (Xanax) 0.5 mg ≈ diazepam 5 mg (alprazolam 2 mg/day = diazepam 20 mg equivalent)

Lorazepam (Ativan) 1 mg ≈ diazepam 10 mg (lorazepam 4 mg/day = diazepam 40 mg equivalent)

Clonazepam (Klonopin) 0.5 mg ≈ diazepam 10 mg (clonazepam 2 mg/day = diazepam 40 mg equivalent)

Temazepam 10 mg ≈ diazepam 10 mg

Calculate total daily diazepam equivalent before assessing dose category.

Yes. Alprazolam 2 mg TID = 6 mg/day alprazolam = approximately diazepam 60 mg equivalent — well above the 40 mg threshold. Alprazolam is additionally concerning because of its short half-life, which produces significant interdose withdrawal and makes it one of the most difficult benzodiazepines to taper.

This patient needs psychiatry e-consult before you continue prescribing at this dose. Document the equivalent calculation in the chart.

Yes — do not reduce or discontinue while the consult is pending. Prescribe one month at the current dose, document your awareness of the dose threshold, document that specialist input is pending, and schedule a follow-up for shortly after the expected consult response.

Institutional support applies when you are actively working the framework.

Gabapentin and pregabalin have sedating and respiratory depressant properties that are potentiated by benzodiazepines. The combination has been increasingly associated with overdose deaths, particularly in patients with underlying respiratory disease or concurrent opiate use.

The FDA added a warning on this combination in 2019. A patient on a benzodiazepine plus gabapentin plus an opiate is in the highest risk tier regardless of individual doses.

Yes — Z-drugs (zolpidem, eszopiclone, zaleplon) act on the same GABA-A receptors as benzodiazepines and produce additive CNS depression. This combination is explicitly flagged in Beers Criteria and FDA guidance.

At this visit: document the combination, counsel the patient on the risk, and identify which agent is primary. CBT-I is the appropriate long-term intervention for the insomnia component. Eliminating the Z-drug is generally lower risk than addressing the benzodiazepine first.

Contact the prescribing provider. Concurrent benzodiazepine and muscle relaxant prescribing (cyclobenzaprine, methocarbamol, carisoprodol) represents a polypharmacy CNS depressant burden that requires coordination.

Carisoprodol (Soma) is particularly high-risk — it is metabolized to meprobamate, a barbiturate-like compound with significant abuse potential. Document your communication with the orthopedic provider and the agreed plan.

Three pathways:

(1) Establish an indication at this visit through clinical assessment — administer GAD-7, PHQ-9, ask about panic attacks, take a sleep history. If a condition is present, diagnose and document it.

(2) If no indication can be established and the patient is physically dependent, e-consult to psychiatry with the explicit question: "Patient on chronic benzodiazepine without documentable indication. Please advise on taper planning and whether any psychiatric diagnosis is present."

(3) If the patient declines evaluation and insists on continuation without any clinical basis, document the conversation, document your clinical assessment, and make a reasoned decision about whether you can continue prescribing — knowing that "no indication" is a significant documentation liability.

No — documenting a diagnosis you have not clinically assessed is not a solution and creates its own liability. If anxiety is present, assess it properly and document your assessment. If it is not present, do not fabricate it.

The four-minute GAD-7 exists precisely so that this question has a documented answer.

Multiple converging risks: falls and hip fractures (benzodiazepines impair balance, reaction time, and depth perception), cognitive impairment (both acute confusion and potential long-term dementia risk with chronic use), paradoxical agitation in some older patients, and prolonged half-life of many agents in older adults due to reduced hepatic metabolism.

The American Geriatrics Society Beers Criteria explicitly lists all benzodiazepines as potentially inappropriate in adults ≥ 65 regardless of indication.

This is one of the most delicate scenarios in primary care. A 15-year history of daily use in a 72-year-old represents profound physical dependence, and taper carries real risks including withdrawal seizure and severe anxiety.

The answer is not to continue unchanged and not to taper abruptly — it is to have an honest, unhurried conversation, document the risks of both continuation and taper, involve the patient in the decision, and obtain psychiatry e-consult for a guided taper plan if the patient is willing. For patients who are clearly not candidates for taper given age, functional status, and risk-benefit calculation, documenting that reasoning explicitly is a defensible position.

Yes — chronic benzodiazepine use is associated with accelerated cognitive decline and may be contributing to or causing the impairment. This does not mean the medication caused the dementia, but it is a modifiable risk factor that should be addressed.

Involve neurology or geriatrics if the cognitive picture is complex. Document that the association has been considered.

Tolerance to the anxiolytic effect of benzodiazepines is expected with chronic use — this is pharmacology, not failure. The appropriate response is not to increase the dose.

The appropriate response is: "What you're describing is something that happens with long-term use of this medication — it becomes less effective over time. The answer isn't more of the same medication; it's finding an approach that works better long-term." This is the moment to introduce SSRIs, SNRIs, buspirone, or therapy as alternatives — not as replacements to be implemented today, but as a direction of travel. Document the conversation and initiate e-consult to psychiatry for transition planning.

In primary care, for chronic anxiety management, dose escalation of an established benzodiazepine regimen is almost never the right answer and should not occur without psychiatry input. There are narrow exceptions — acute situational escalation for a defined procedure or crisis — but these are time-limited and do not represent chronic dose increases.

If a patient's anxiety is inadequately controlled on their current regimen, the clinical question is whether the underlying condition is being managed appropriately, not whether the benzodiazepine dose should be higher.

With clarity and without apology: "I understand you're frustrated, and I want to help you feel better. I'm not able to increase this medication — that's a clinical decision, not a personal one. What I can do is work with you on finding something that addresses the underlying anxiety more effectively."

Document the request, your response, and the patient's reaction. A patient who leaves the practice over a refusal to escalate a benzodiazepine dose has self-selected out of a framework that was designed to protect them.

Standard laboratory reference ranges:

Microcytic: MCV < 80 fL — think iron deficiency first, then thalassemia, then anemia of chronic disease (can be microcytic), then sideroblastic anemia (rare).

Normocytic: MCV 80–100 fL — think anemia of chronic disease, early iron deficiency, renal anemia, hypothyroidism, mixed deficiency, or early bone marrow pathology.

Macrocytic: MCV > 100 fL — think B12 deficiency, folate deficiency, hypothyroidism, alcohol use, medications (methotrexate, hydroxyurea, zidovudine), or myelodysplastic syndrome in older patients.

MCV is your first branch point. Every subsequent test order flows from this categorization.

Normocytic anemia is the broadest category and requires the most differential thinking. Anemia of chronic disease is common but should be a diagnosis of context — meaning the patient has a known chronic inflammatory condition (rheumatoid arthritis, IBD, malignancy, CKD) that explains it.

Normocytic anemia without a clear chronic disease context requires reticulocyte count as the next step to distinguish between underproduction and loss or destruction.

Elevated RDW (red cell distribution width) indicates anisocytosis — a mixed population of cell sizes. This is particularly useful in two scenarios:

(1) A microcytic anemia with high RDW suggests iron deficiency rather than thalassemia (thalassemia tends to have normal or low RDW despite low MCV).

(2) A normocytic anemia with high RDW may indicate a mixed deficiency — iron plus B12 or folate — where the two processes cancel each other out in terms of MCV while the RDW reflects the heterogeneity. When the MCV looks normal but the RDW is high, order both iron studies and B12/folate.

Yes — the differential provides information the MCV alone cannot. Hypersegmented neutrophils (≥ 5 lobes) are a classic finding in B12 or folate deficiency and may precede macrocytosis. Target cells suggest hemoglobinopathy or liver disease.

Schistocytes (fragmented RBCs) indicate microangiopathic hemolytic anemia — TTP, HUS, DIC — and are an emergency finding. If you see schistocytes on a differential, escalate immediately.

The reticulocyte count tells you what the bone marrow is doing in response to the anemia. A normal bone marrow facing anemia should increase production — reticulocytes should rise. If they don't, the problem is in the bone marrow or in the substrate (iron, B12, folate). If they are elevated, the marrow is responding appropriately, which means the problem is peripheral — blood loss or destruction (hemolysis).

Use the reticulocyte production index (RPI) rather than the raw reticulocyte percentage, which is misleading in anemia because it is expressed as a percentage of a smaller RBC pool:

RPI = (reticulocyte % × patient hematocrit) ÷ 45

RPI < 2: hypoproliferative — bone marrow is not responding appropriately. Think iron deficiency, B12/folate deficiency, anemia of chronic disease, renal anemia, or bone marrow pathology.

RPI > 2: hyperproliferative — marrow is responding. Think hemolysis or acute blood loss.

A raw percentage without the RPI calculation is limited — you need to interpret it in context. A reticulocyte percentage of 2.5% sounds elevated but may represent an RPI of 1.2 in a severely anemic patient, indicating an inadequate response.

Do the RPI calculation yourself using the formula above and document it in the note.

Ferritin is the most sensitive single marker for iron deficiency when low — a ferritin < 30 ng/mL is highly specific for iron deficiency in most clinical contexts. However, ferritin is an acute phase reactant and is elevated by inflammation, infection, liver disease, and malignancy.

A patient with an inflammatory condition can have a ferritin of 80 ng/mL and still be iron deficient. In the context of chronic inflammation, a ferritin up to 100 ng/mL does not exclude iron deficiency — transferrin saturation < 20% in this context supports the diagnosis. Use the full panel: serum iron, TIBC, ferritin, and transferrin saturation together.

Oral iron is first-line for most patients:

Ferrous sulfate 325 mg (65 mg elemental iron) every other day — as effective as daily dosing with significantly fewer GI side effects. This is a meaningful recent evidence update from the older twice-daily standard.

Take on an empty stomach with vitamin C (orange juice) to maximize absorption. Avoid within 2 hours of calcium, antacids, PPIs, or thyroid medication.

Recheck CBC and reticulocyte count in 4 weeks — you should see reticulocyte response within 1–2 weeks and hemoglobin rise of 1–2 g/dL by 4 weeks if the diagnosis and absorption are correct.

Continue treatment for 3 months after hemoglobin normalizes to replete stores.

IV iron is appropriate and effective for patients with malabsorption, intolerance to oral iron, inflammatory bowel disease, or who are on PPIs that cannot be discontinued. IV iron formulations (ferric carboxymaltose, low molecular weight iron dextran, ferumoxytol) can be administered in an infusion center.

This is within primary care scope to order — you do not need hematology referral to initiate IV iron in uncomplicated iron deficiency anemia.

In most cases yes — iron deficiency in an adult is blood loss until proven otherwise. In premenopausal women with heavy menstrual bleeding, the source is often clinically apparent and colonoscopy is not mandatory in the absence of GI symptoms or red flags.

In men and postmenopausal women, iron deficiency requires GI evaluation — upper endoscopy and colonoscopy — to exclude occult GI blood loss including malignancy. Do not treat iron deficiency in a postmenopausal woman or any man without addressing the question of GI source.

Possibly — this pattern (normal or elevated ferritin, low transferrin saturation) in the context of chronic inflammation is called functional iron deficiency or iron-restricted erythropoiesis. The iron exists in stores but is not being released for use. This is distinct from absolute iron deficiency and is the hallmark of anemia of chronic disease with iron restriction.

Treatment depends on the underlying condition — treating the inflammation is the primary intervention, supplemental iron has limited benefit in pure anemia of chronic disease, and IV iron may be considered in select cases (particularly CKD — see CKD module).

Always order both when MCV > 100. Also consider ordering in: normocytic anemia with elevated RDW, hypersegmented neutrophils on differential, neurological symptoms (peripheral neuropathy, cognitive change, balance problems), history of gastric bypass or significant GI resection, strict vegan diet without supplementation, chronic PPI use (reduces B12 absorption over years), metformin use (reduces B12 absorption — check annually in long-term users), or active alcohol use disorder.

No — serum B12 is an unreliable marker at the low-normal range. Levels between 200–400 pg/mL can be associated with functional deficiency, particularly in symptomatic patients.

If clinical suspicion is present, order methylmalonic acid (MMA) and homocysteine — both are elevated in B12 deficiency and are more sensitive markers of functional deficiency than serum B12 alone. A normal MMA effectively excludes B12 deficiency regardless of the serum level.

Treat first, investigate in parallel. B12 deficiency with neurological symptoms is a semi-urgent treatment situation — neurological damage from B12 deficiency can be permanent if prolonged. Initiate replacement immediately.

The most common cause in older adults is pernicious anemia (autoimmune gastritis with intrinsic factor deficiency) — check anti-intrinsic factor antibody and anti-parietal cell antibody. If pernicious anemia is confirmed, parenteral B12 (IM cyanocobalamin) is traditionally used, though high-dose oral B12 (1000–2000 mcg daily) is absorbed adequately via passive diffusion even without intrinsic factor and is now considered equivalent by most guidelines.

Folate deficiency is simpler in etiology — it is almost always dietary (poor intake, alcohol use disorder, malabsorption) or medication-related (methotrexate, trimethoprim, phenytoin). Unlike B12 deficiency, folate deficiency does not cause neurological symptoms — if a macrocytic anemia patient has neurological symptoms, look harder at B12 regardless of folate level.

Treatment is oral folic acid 1 mg daily. Identify and address the underlying cause — folate deficiency in a patient not on a causative medication should prompt dietary and alcohol use assessment.

Methotrexate causes macrocytosis by folate antagonism — this is an expected pharmacological effect and does not necessarily indicate deficiency or require dose change. However, if the anemia is significant or the patient is symptomatic, check folate level and ensure they are on folic acid supplementation (standard with methotrexate therapy).

Coordinate with the prescribing provider before making changes to the methotrexate regimen.

Chest pain, dyspnea at rest, tachycardia, hypotension, syncope, or altered mental status in the context of anemia require same-day evaluation regardless of the absolute hemoglobin level.

A patient with hemoglobin of 9 g/dL who is having chest pain and tachycardia is more urgent than a patient with hemoglobin of 6.5 g/dL who is ambulatory and asymptomatic. Symptoms drive urgency more than numbers.

Transfusion thresholds in stable outpatients:

Hemoglobin < 7 g/dL — transfusion is generally indicated in symptomatic patients. In asymptomatic, young, otherwise healthy patients with a clearly reversible cause (iron deficiency being actively treated), watchful waiting with close monitoring is sometimes appropriate — discuss with hematology.

Hemoglobin 7–8 g/dL — transfusion guided by symptoms and underlying condition. Patients with cardiac disease or limited cardiopulmonary reserve may need transfusion at higher thresholds.

Hemoglobin > 8 g/dL — transfusion rarely indicated in stable outpatients without active bleeding or severe symptoms.

Outpatient transfusion can be arranged through infusion centers — this does not require ER admission for a stable but significantly anemic patient.

Not necessarily — if the patient is stable, ambulatory, not having chest pain or tachycardia, and you can arrange outpatient transfusion within 24–48 hours, this is manageable without an ER visit. Call the infusion center, arrange the transfusion, and ensure the patient has clear return precautions.

If outpatient transfusion cannot be arranged promptly or the patient's condition is at all unstable, send to the ER with a direct communication to the receiving team.

Review this list before the e-consult:

Hypothyroidism — TSH should be part of any unexplained normocytic or macrocytic anemia workup.

Renal insufficiency — check creatinine and eGFR; anemia of CKD is common and underrecognized.

Chronic liver disease — LFTs, consider hepatitis screening.

Lead toxicity — in patients with occupational exposure, recent immigration from high-exposure regions, or pica; order blood lead level.

Medication review — many drugs cause anemia through various mechanisms; review the full medication list.

Alcohol use — often underreported; ask directly.

Inflammatory markers — ESR, CRP, ferritin as acute phase reactant; anemia of chronic inflammation may not have an obvious clinical source.

Be specific and include your workup: "Patient with [degree] [MCV category] anemia, hemoglobin [X]. Workup completed: iron studies [results], B12 [result], folate [result], reticulocyte count/RPI [result], TSH [result], CMP [result]. No clear etiology identified. No evidence of hemolysis. CBC differential without abnormal forms. Requesting evaluation for underlying cause and management recommendation."

A hematologist receiving this consult can move directly to the next tier of evaluation rather than repeating your workup.

The hemolysis panel: elevated LDH (released from lysed RBCs), elevated indirect bilirubin (from heme catabolism), low or undetectable haptoglobin (binds free hemoglobin and is consumed), and elevated reticulocyte count/RPI (marrow responding to peripheral destruction).

Not all markers need to be abnormal simultaneously — low haptoglobin alone has high specificity for hemolysis. Order the full panel and document which markers are positive.

Categorize by mechanism:

Immune-mediated — warm autoimmune hemolytic anemia (AIHA). Order direct antiglobulin test (DAT/Coombs). A positive DAT confirms immune-mediated destruction and is the most common cause of hemolysis in primary care patients. Associated with autoimmune conditions, CLL, and certain medications (methyldopa, penicillin, cephalosporins).

Microangiopathic — schistocytes on smear: TTP, HUS, DIC, malignant hypertension. This is an emergency — do not manage outpatient.

Hereditary — G6PD deficiency (often triggered by infection, oxidative drugs, fava beans — order G6PD level), hereditary spherocytosis (spherocytes on smear, family history), sickle cell disease (usually known).

Treat as urgent. Schistocytes indicate microangiopathic hemolytic anemia — RBCs being sheared by damaged small vessels. TTP (thrombotic thrombocytopenic purpura) is life-threatening and time-sensitive — check platelet count immediately.

Thrombocytopenia plus microangiopathic hemolytic anemia is TTP until proven otherwise and requires same-day hematology contact, not an e-consult. Send the patient to the ER with a direct communication.

Bicytopenia (two cell lines low) is a more concerning finding than isolated anemia. The differential includes: bone marrow failure (aplastic anemia), infiltrative bone marrow process (hematologic malignancy, metastatic solid tumor), hypersplenism, autoimmune destruction of multiple cell lines, B12/folate deficiency (can cause pancytopenia), or medications (chemotherapy, immunosuppressants, some antibiotics).

This requires hematology e-consult — not after a prolonged workup, but promptly.

Context matters. Atypical lymphocytes are common in viral infections — EBV (infectious mononucleosis), CMV, and other viral syndromes produce reactive atypical lymphocytes that are benign and self-limited. In a young patient with fever, pharyngitis, and lymphadenopathy, check monospot and EBV titers.

In an older patient without a viral prodrome, persistent atypical lymphocytes or a lymphocytosis that doesn't resolve warrants hematology e-consult to evaluate for lymphoproliferative disease.

Contact hematology today — do not wait for an e-consult response. Blasts on a peripheral smear suggest acute leukemia until proven otherwise. This is a same-day phone call to hematology, not a portal message.

While arranging urgent evaluation, do not start any new medications that could affect the marrow picture. Be direct with the patient that you have found something that requires urgent specialist evaluation.

An adequate trial requires: correct diagnosis (confirmed iron deficiency, not anemia of chronic disease), correct dose (ferrous sulfate 325 mg on alternate days or equivalent), correct administration (empty stomach, with vitamin C, away from PPIs and calcium), and sufficient duration (minimum 4 weeks for reticulocyte response, 8–12 weeks for meaningful hemoglobin rise).

Before calling a trial a failure, verify all four. The most common reason for apparent treatment failure is PPI use that was not addressed.

Ongoing blood loss exceeding replacement — the source has not been identified or is continuing. Malabsorption — celiac disease, gastric bypass, inflammatory bowel disease, H. pylori gastritis. Incorrect diagnosis — reconsider whether this is truly iron deficiency or functional iron deficiency in the context of inflammation.

H. pylori infection specifically is associated with refractory iron deficiency anemia and should be tested if not already done (urea breath test or stool antigen).

IV iron is appropriate when oral iron has genuinely failed after an adequate trial, when malabsorption is confirmed or strongly suspected, when the patient cannot tolerate oral iron, or when rapid repletion is needed (preoperative optimization, severe symptomatic anemia).

IV iron does not require hematology referral — it can be ordered by primary care and administered in an infusion center. Refractory iron deficiency that fails IV iron, or iron deficiency without an identified source in a patient who has had appropriate GI evaluation, is the threshold for hematology e-consult.

Anemia of CKD is normocytic and normochromic, caused primarily by reduced erythropoietin production by the damaged kidneys. It typically becomes clinically apparent at eGFR < 45 (G3b) and is nearly universal at G4–G5.

It is a diagnosis of exclusion in the context of CKD — meaning iron deficiency, B12 deficiency, and other causes should be ruled out before attributing anemia solely to CKD. Many CKD patients have coexisting iron deficiency that is treatable and should be corrected before considering erythropoiesis-stimulating agents.

Complete the standard Meridian anemia workup first — CBC with differential, reticulocyte count, iron studies, B12, folate. Additionally order PTH, phosphorus, and 25-OH vitamin D if not recently done as part of CKD mineral metabolism assessment.

Then cross-reference with the Meridian CKD module for integrated management. The CKD e-consult to nephrology should include the anemia workup so the nephrologist can advise on ESA candidacy with complete information.

ESA initiation is a nephrology decision in the primary care context. Your role is to identify the anemia, complete the workup, correct any iron deficiency (IV iron preferred in CKD — oral iron is poorly absorbed in CKD patients and worsens constipation), and document.

Do not initiate ESA therapy without nephrology input — ESAs carry risks including accelerated cardiovascular events and increased tumor progression risk in malignancy, and dosing requires monitoring that is typically managed by nephrology.